Rocket Lab USA, Inc. Q3 FY2025 earnings call

• Launch Performance: Record-breaking quarter with $155 million revenue (+48% YoY). Electron has 49 launches on contract, with 17 new bookings in Q3, including international customers. Seventeenth launch of the year expected soon, surpassing 2024's launch record.
• Space Systems Progress: Twin spacecraft for NASA Mars mission near launch; Transport Layer Constellation for SDA cleared critical design review. Acquisitions like Geos strengthened payload capabilities; progress towards acquiring Manaruk.
• Neutron Update: Targeted Q1 2026 for first flight, with extensive testing of structures, engines, and recovery systems. Launch Complex 3 opened in August, with plans to turn missions within 24 hours.
• Financials: Q3 revenue $155 million (+48% YoY), GAAP gross margin 37%, non-GAAP gross margin 41.9%. Ended Q3 with $1.1 billion backlog, 53% in space systems.

Launch Services: Q3 revenue was $40.9 million, a 12.3% QoQ decline due to fewer launches. Launch backlog accounts for approximately 47% of the $1.1 billion total backlog. Electron saw 17 new bookings in the quarter, with strong international customer demand. Space Systems: Q3 revenue was $114.2 million, a 16.7% QoQ increase. Space systems backlog represents 53% of total backlog. Progress includes twin spacecraft for NASA Mars mission near launch, Transport Layer Constellation for SDA clearing critical design review, and acquisitions like Geos and progress towards acquiring Manaruk.

• Q4 Revenue: Expected to range $171 million to $180 million, a 12.8% QoQ growth at midpoint.
• Gross Margins: GAAP gross margins forecasted to be 37%-39% and non-GAAP to be 43%-45% in Q4, driven by higher launch contribution and improved average selling prices.
• Operating Expenses: GAAP operating expenses expected to range $122 million to $128 million and non-GAAP to range $107 million to $113 million, driven by Neutron development spending.
• Net Income: Anticipated $3.5 million in Q4, due to higher cash balances and convertible note conversions.
• Adjusted EBITDA: Loss expected to range $23 million to $29 million in Q4.

• Government Shutdown Impact: Slower cash receipts, but a large payment from SDA was received recently. The shutdown hasn't significantly affected internal outlooks yet but could if prolonged.
• Neutron Development Risks: Delays in testing and qualification processes could impact the timeline for Neutron's first flight and subsequent launch cadence.

Q: Ryan Koontz asked about international bookings and Electron's supply chain.

A: Peter Beck noted strong international bookings with both commercial and space agency customers, and Electron is 90%+ built in-house, so supply chain isn't a major concern.

Q: Andres Sheppard inquired about space systems revenue recognition and Neutron cadence.

A: Adam Spice discussed space systems revenue recognition timelines, and Peter Beck mentioned Neutron's first launch is targeted for early 2026, with cadence starting from the first flight.

Q: Gautam Khanna questioned Neutron's launch timeline and engine production.

A: Peter Beck stated Neutron's launch timeline depends on testing outcomes, and Adam Spice mentioned engines are on test stands with progress on the recovery barge.

Q: Andre Madrid asked about the impact of the government shutdown.

A: Peter Beck said the government shutdown hasn't dramatically affected Rocket Lab, with a recent large cash payment from SDA.

Q: Anthony Valentini inquired about Neutron's backlog and differentiation.

A: Adam Spice said there are two fully priced Neutron missions in backlog, and Peter Beck highlighted vertical integration and reliability as key differentiators.

Q: Kristine T. Liwag asked about M&A priority and spectrum.

A: Peter Beck mentioned focus on tuck-in acquisitions, payload ownership, and strategic elements for step-change growth.

Q: Peter Arment asked about Electron demand and Archimedes testing.

A: Peter Beck noted upward demand trajectory for Electron, and explained Archimedes testing is more intensive due to dual ascent and descent environments.